EFFICACY AND SAFETY OF ANTISCABIETIC AGENTS : A SYSTEMATIC  REVIEW

Ilma Fitriana

doi:10.53555/jwst5434

Authors

Ilma Fitriana Faculty of Medicine, Trisakti University Author

DOI:

https://doi.org/10.53555/jwst5434

Keywords:

Antiscabietic agent, Ivecmetrin, Primetherin, Scabies

Abstract

Scabies is a contagious skin condition that is caused by a mite called Sarcoptes scabiei. This mite burrows into the skin and causes a severe itching sensation. Scabies can be spread either directly from person to person through scratching or indirectly through contact with contaminated surfaces or objects (fomites). Due to the fact that many people may only exhibit mild symptoms, accurate diagnosis of this ailment can be challenging at times. Scabies can be effectively treated with a variety of different medications. However, clinical trials comparing the efficacy of these treatments, in particular the available topical agents, are relatively few in number. As a consequence, prescribing practice varies greatly from country to country and is largely determined by factors such as the cost and availability of treatments as well as the individual preference of the treating physician. Permethrin, oral ivermectin, and synergized pyrethrins appeared to provide the best balance between these two outcomes compared to the other treatments. These three treatments were located closer to the right upper corner of the clustered ranking plot than the other treatments. On the other hand, the fact that the adverse events (AEs) that were reported in these trials were not serious adverse reactions (such as hospitalization or death) means that one could rationally give them less weight than the cure. Our study found that ivermectin and permethrin were the most effective treatments. The antiscabietic agents used in this study had few or manageable adverse effects, and the study did not find any severe adverse effects.

References

Micali G, Lacarrubba F, Verzì AE, Chosidow O, Schwartz RA. Scabies: Advances in Noninvasive Diagnosis. PLoS Negl Trop Dis. Juni 2016;10(6):e0004691.

Vasanwala FF, Ong CY, Aw CWD, et al. Management of scabies. Singapore Med J. 2019;60(6):281–5.

Swe PM, Christian LD, Lu HC, Sriprakash KS, Fischer K. Complement inhibition by Sarcoptes scabiei protects Streptococcus pyogenes - An in vitro study to unravel the molecular mechanisms behind the poorly understood predilection of S. pyogenes to infect mite-induced skin lesions. PLoS Negl Trop Dis. Maret 2017;11(3):e0005437.

Habif T. Clinical Dermatology. New York: Elsevier Churchill Livingstone;2015.

James W, Berger T, Elston D. Andrews’ Disease of the Skin, Clinical Dermatology. Philadelphia: Elsevier Health Sciences; 2015.

Anderson KL, Strowd LC. Epidemiology, Diagnosis, and Treatment of Scabies in a Dermatology Office. JAm Board Fam Med. 2017;30(1):78–84.

Dressler C, Rosumeck S, Sunderkötter C, et al. The Treatment of Scabies. Dtsch ArzteblInt. 2016;113(45):757–62.

Widaty S, Miranda E, Cornain EF, Rizky LA. Scabies: update on treatment and efforts for preventionand control in highly endemic settings. J Infect Dev Ctries. 2022;16(02):244–51.

Rezaee E, Goldust M, Alipour H. Treatment of Scabies: Comparison of Lindane 1% vs Permethrin 5. Skinmed. 2015;13(4):283–6.

Ahmad HM, Abdel‐Azim ES, Abdel‐Aziz RT. Clinical efficacy and safety of topical versus oral ivermectin in treatment of uncomplicated scabies. Dermatol Ther. 2016;29(1):58–63.

Alipour H, Goldust M. The efficacy of oral ivermectin vs. sulfur 10% ointment for the treatment of scabies. Ann Parasitol. 2015;61(2).

Goldust M, Rezaee E, Raghifar R. Comparison of oral ivermectin versus crotamiton 10% cream inthe treatment of scabies. Cutan Ocul Toxicol. 2014;33(4):333–6.

Chandler DJ, Fuller LC. A Review of Scabies: An Infestation More than Skin Deep. Dermatology[Internet]

;235(2):79–90. Tersedia pada:https://www.karger.com/DOI/10.1159/000495290

Richards RN. Scabies: diagnostic and therapeutic update. J Cutan Med Surg. 2021;25(1):95–101.

May PJ, Tong SYC, Steer AC, Currie BJ, Andrews RM, Carapetis JR, et al. Treatment, prevention and public health management of impetigo, scabies, crusted scabies and fungal skin infections in endemic populations: a systematic review. Trop Med Int Heal. 2019;24(3):280–93.

Golant AK, Levitt JO. Scabies: a review of diagnosis and management based on mite biology. PediatrRev. 2012;33:1–12.

Engelman D, Cantey PT, Marks M, Solomon AW, Chang AY, Chosidow O, et al. The public health control of scabies: priorities for research and action. Lancet. 2019;394(10192):81–92.

Centers for Disease Control and Prevention National Center for Health Statistics. Epidemiology & RiskFactors

[Internet] Scabies. 2010. Tersedia pada:https://www.cdc.gov/parasites/scabies/epi.html [19] Strong M, Johnstone P. Interventions for treating scabies. Cochrane database Syst Rev.Juli 2007;2007(3):CD000320.

Rosumeck S, Nast A, Dressler C. Ivermectin and permethrin for treating scabies. Cochrane Database SystRev. 2018;(4).

Currie BJ, McCarthy JS. Permethrin and ivermectin for scabies. N Engl J Med. 2010;362(8):717–25.

Administration USF and D. FDA public health advisory: safety of topical lindane products for the treatmentof scabies and lice. 2009.

Gonzalez P, a González F, Ueno K. Ivermectin in human medicine, an overview of the current status ofits clinical applications. Curr Pharm Biotechnol. 2012;13(6):1103–9.

Kamgno J, Boussinesq M, Labrousse F, Nkegoum B, Thylefors BI, Mackenzie CD. Encephalopathy after ivermectin treatment in a patient infected with Loa loa and Plasmodium spp. Am J Trop Med Hyg. April 2008;78(4):546–51.

Lobo Y, Wheller L. A narrative review of the roles of topical permethrin and oral ivermectin in the management of infantile scabies. Australas J Dermatol. 2021;62(3):267–77.